This paper is in the following e-collection/theme issue:

Authors' Responses to Peer-Reviews (92)

Published on in Vol 5 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/58273, first published .
Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Authors of this article:

Tigran Makunts1 Author Orcid Image ;   Haroutyun Joulfayan2 Author Orcid Image ;   Ruben Abagyan1 Author Orcid Image
Article Authors Cited by Tweetations (3) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.